Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Thomson et al suggest that variations in recommendations for
anticoagulant treatment of atrial fibrillation could be overcome by
having a single body responsible for producing evidence based
guidelines.1 Might giving this responsibility to one body
lead to a form of medical tyranny in which only one view of who should
be offered anticoagulant treatment is held to be valid? Evidence based
medicine does not preclude the role of the patient in choosing or
declining a particular treatment.2
The evidence base for anticoagulant treatment of non-rheumatic atrial
fibrillation is strongly influenced by just six trials, five of which
have been conveniently pooled. All suggest that anticoagulation with
warfarin is beneficial. Further analyses of the data have attempted
to stratify differing degrees of risk and potential
benefits.3 Evidence based guidelines that could convey
this information to clinicians would be welcome, but to suggest that
this evidence can then determine the